Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




China Fake Drug Scandal Claims 14th Victim: Xinhua
Link ID 2695
Title China Fake Drug Scandal Claims 14th Victim: Xinhua
Url http://www.medscape.com/viewarticle/569234?src=rss
Description A batch of fake Chinese medicine claimed its 14th victim when a man died of kidney failure nearly two years after receiving a tainted injection, state media said. Reuters Health Information
Category Articles > Business of Medicine
Keywords
Date Jan 26, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Business of Medicine
1. Wyeth Says FDA OKs Oral Suspension Version of Heartburn Drug
  Wyeth said U.S. health regulators approved a delayed-release oral suspension version of its heartburn drug Protonix. Reuters Health Information
Category:   Articles > Business of Medicine


2. Magellan Health Q3 Profit Beats Street
  Magellan Health Services Inc, which provides a network of doctors and hospitals to its members, posted a quarterly profit that beat market expectations, and reaffirmed its 2008 outlook. Reuters Health Information
Category:   Articles > Business of Medicine


3. CellCept Labeling Changes Reflect PML Risk
  Healthcare providers should include progressive multifocal leukoencephalopathy in the differential diagnosis of immunosuppressed patients presenting with focal neurologic symptoms. Medscape Medical News
Category:   Articles > Business of Medicine


4. Aetna Wins Expanded Contract From Bank of America
  Aetna Inc will become the primary U.S. carrier of health Insurance and other benefits for Bank of America next year, the companies said on Thursday, giving the insurer a major contract win. Reuters Health Information
Category:   Articles > Business of Medicine


5. No HOPE Without Proof: Do ARBs Meet the Standard for Cardiovascular Protection?
  RAS blockade by ACEIs or ARBs is of proven benefit for cardiovascular disease, but whether either is superior to their combination is unknown. Evidence will be available in 2008 from ONTARGET trial.
The Medscape Journal of Medicine
Category:   Articles > Business of Medicine




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS